Emergent BioSolutions Inc. — Director's Dealing 2023

Aug 15, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2023-08-08

Reporting Person: Hartzel William (SVP, Bioservices)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	35917	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Options (Right to Buy)	$42.28	2029-04-07	Common Stock (11826)		Direct
Employee Stock Options (Right to Buy)	$11.66	2030-03-05	Common Stock (3077)		Direct
Employee Stock Options (Right to Buy)	$8.39	2030-06-08	Common Stock (12308)		Direct

Footnotes

F1: Consists of 2,230 shares of common stock, including 800 shares purchased through the Company's Employee Share Purchase Program, and 25,994 unvested RSUs and 7,693 unvested PSUs granted from the Emergent Stock Incentive Plan. Each RSU and PSU represents a right to receive one share of common stock. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

F2: This Employee Stock Option award is 1/3 vested and exercisable and 2/3 unvested as of the filing of this Form 3. The unvested Employee Stock Options vest in annual installments beginning on the day prior to the anniversary date of the grant.

F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.